Cite
HARVARD Citation
Berestjuk, I. et al. (2022). Targeting Discoidin Domain Receptors DDR1 and DDR2 overcomes matrix‐mediated tumor cell adaptation and tolerance to BRAF‐targeted therapy in melanoma. EMBO molecular medicine. 14 (2), p. n/a. [Online].